Anavex Life Sciences Corp (AVXL)

[BIOChecker4]

With 9 trading days left in 2022 (including today), below are the 6 remaining “catalysts” that have been touted and pumped for many months. It’s unbelievable how Chris Miss keeps shooting himself in the foot to the detriment of patients and shareholders.

1. Data of 48-week OLE PDD Phase 2 study – expected by end 2022
2. EXCELLENCE completion: Potentially pivotal Phase 2/3 pediatric RTT clinical trial – expected by end 2022
3. Initiation of ANAVEX®2-73 imaging-focused Parkinson’s disease clinical trial – expected 2022
4. Initiation of potentially pivotal ANAVEX®2-73 Phase 2/3 Fragile X clinical trial – expected 2022
5. Initiation of potentially pivotal ANAVEX®2-73 Phase 2/3 clinical trial for the treatment of a new, rare disease indication – expected 2022
6. Initiation of ANAVEX®3-71 Phase 2 clinical trial for FTD, schizophrenias and Alzheimer’s disease – expected 2022